^
Association details:
| Biomarker: | UGT1A1*28 + UGT1A1*6 |
|---|---|
| Cancer: | Pancreatic Cancer |
| Regimen: | (leucovorin calcium + oxaliplatin + 5-fluorouracil + irinotecan) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study
Published date:
01/02/2021
Excerpt:
Advanced PC patients with UGT1A1-DV who had received at least one cycle of FOLFIRINOX...response rate (RR) and progression-free survival (PFS) in patients given irinotecan of ≤ 120 mg/m2 were 21.4% and 8.1 months, respectively....we recommend that in Japanese advanced PC patients with UGT1A1- DV treated with FOLFIRINOX, irinotecan be administered at an initial dose of ≤ 120 mg/m2.
DOI:
10.1007/s00280-020-04206-w
